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Promotion in Urinary Bladder
Carcinogenesis
by Samuel M. Cohen*
Aromatic amines, including 2-naphthylamine, 4-aminobiphenyl and benzidine, are known urinary
bladder carcinogens in man and other species, but in rodents, aromatic amines and amides have
usually induced liver tumors, occasionally also with tumors of the bladder and other tissues. Varia-
tions in organ specificity are related to differences in metabolism; for the production of bladder tu-
mors, the rates of acetylation and deacetylation appear to be critical. Bladder specific carcinogens
in rodents and other species have subsequently been identified, including N-butyl-N-4-hydroxy-
butyl)nitrosamine (BBN) administered in the drinking water, N-[(445-nitro-2-furyl-2-thi-
azolyllformamide (FANFT) in the diet and N-methyl-N-nitrosourea (MNU) instilled intravesically.
When low doses of several bladder carcinogens (BBN, FANFT, 2-acetylaminofluorene, and
3,3'-dichlorobenzidine) are administered to rats, either simultaneously or sequentially, a synergistic
effect is observed with respect to bladder carcinogenesis. In addition, a multistage carcinogenesis
process has been demonstrated for the rat bladder using MNU or FANFT as initiators, and dietary
sodium saccharin, sodium cyclamate, or tryptophan as promoters. Calculi (or pellets) appear to en-
hance the promotion process but are not necessary for it to occur. Recent studies also indicate that
urine has a role in the promoting process. The urothelium normally has a very low mitotic rate. If
mucosal proliferation is increased, such as during fetal development or during regeneration and re-
pair of an ulcer, the bladder appears to be considerably more sensitive to the effects of promoting
substances. For example, if sodium saccharin is administered to rats after ulceration of the bladder,
even without prior administration of an initiator, bladder carcinoma develops. Under these condi-
tions, the substance appears as a carcinogen. Human populations with increased bladder epithelial
proliferation, such as fetus, infants, patients with bacterial cystitis or men with partially obstruc-
tive prostatism, may have increased susceptibility to the action of carcinogenic or promoting
stimuli.
Introduction
Urinary bladder carcinogenesis has been asso-
ciated with exogenous chemicals since the report by
Rehn in 1895, describing the association of bladder
cancer with the German aniline dye industry (1).
Hueper and colleagues (1) were able to demonstrate
that one of the carcinogens to which these workers
were exposed was 2-naphthylamine. These experi-
ments were undertaken with dogs and involved
long periods of time and great expense. Subse-
quently, aromatic amines have been of central im-
portance in the study of chemical carcinogenesis in
general and bladder carcinogenesis (1, 2), specifi-
cally. Such studies have been involved in the use of
experimental animals and humans, and have re-
sulted in the identification of a number of aromatic
amines and amides of significance to human bladder
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carcinogenesis: 2-naphthylamine, benzidine, 4-amino-
biphenyl, phenacetin-containing analgesics (3), and
chlornaphzine. The discovery of the urinary bladder
carcinogenicity of 2-acetylaminofluorene (AAF) in
rodents provided an experimental model for study-
ing urinary bladder carcinogenesis in the rat (1).
However, AAF is not a bladder-specific carcinogen,
inducing also tumors of the liver, mammary gland,
Zymbal's gland, as well as other organs depending
on the species. Metabolic pathways involved in the
activation of these compounds have been studied
extensively and involves the generation of reactive
electrophilic reagents as initially reported by Miller
and Miller (4). However, it was not until the dis-
covery of bladder-specific carcinogens in rodent spe-
cies that additional advancements in the mecha-
nisms of bladder carcinogenesis could be achieved.
These bladder-specific carcinogens included N-butyl-
N(4-hydroxybutyl)nitrosamine (BBN) administered
in the drinking water (5), N-[445-nitro-2-furyl)2-thi-
azolyl]formamide (FANFT) administered in the diet(6) and N-methyl-N-nitrosourea (MNU) administered
intravesicularly (7).
N-[4-(5-Nitro-2-furyl)-2-
thiazolyljformamide (FANFT)
FANFT was initially reported to be a urinary
bladder specific carcinogen in Sprague-Dawley fe-
male rats (6), but was subsequently found to affect
male and female rats as well as mice, hamsters, and
dogs (8). The guinea pig, however, appears to be re-
sistant to the carcinogenic effects of this compound
and other nitrofurans. The course of bladder carci-
nogenesis due to FANFT in these various species is
similar. The urinary bladder epithelium is normally
three cell layers thick, with a large superficial cell
layer, an intermediate cell layer and a basal cell
layer resting on a basement membrane separating
it from the underlying connective tissue (2). During
carcinogenesis the normal three-layered urothelium
progresses to a diffuse, simple hyperplasia followed
by a focal nodular and papillary hyperplasia (6, 9,
10). It must be emphasized that through these
stages the lesions can be reversible, although with
proper stimuli they will progress to cancer (10, 11).
Eventually, there is the formation of papillomas and
noninvasive carcinomas, followed by the develop-
ment of invasive carcinomas and occasionally meta-
stases. The tumors are usually transitional cell in
nature in these species, but squamous cell carcino-
mas are common in mice and focal squamous cell dif-
ferentiation within the tumors is common, particu-
larly in rats. Hydronephrosis is uncommon. Never-
theless, FANFT as well as BBN and MNU in these
species are sufficiently similar to the human disease
to provide considerable useful information. Al-
though the organ specificity of these compounds is
dependent to a large extent on their metabolic path-
ways (4, 12, 13), other factors may also be involved,
including the presence of urine. Although BBN and
FANFT, which are administered orally, are meta-
bolically modified in the liver, it would appear that
metabolic activation within the urothelium, the tar-
get tissue, may be of critical importance for the acti-
vation of these compounds. For example, it has re-
cently been demonstrated (14) that a P450 oxidase
system is present in the urinary bladder epithelium
which is capable of metabolically activating aro-
matic amines. More recently, it has also been dem-
onstrated that other peroxidases, such as prosta-
glandin endoperoxide synthetase can also metabolic-
ally activate aromatic amines and nitro compounds,
and that it is present in large quantities in the mi-
crosomes of the urinary bladder epithelium, includ-
ing the rat bladder epithelium (15).
FANFT in the diet follows a dose response when
chronically administered. If administered in the diet
at levels of 0.2, 0.1, or 0.05% for 30 weeks, nearly
100% of the rats eventually developed bladder can-
cer. At the dose of 0.01% only 1 of 40 rats devel-
oped a bladder tumor, and at lower doses no blad-
der lesions were observed through 2 yr of observa-
tion (16). If administered at a constant dose, 0.2% of
the diet, it would also appear that there is a dose ef-
fect if the time FANFT is administered is changed
(10, 17). If it is administered in the diet for 12 or
more weeks, progressive nodular and papillary hy-
perplastic areas are present in the bladder epithel-
ium which eventually develop into carcinomas if the
animals are observed for one to two years. If it is
fed for 8 to 10 weeks, the nodular and papillary hy-
perplasia regresses, but the animals eventually de-
velop bladder carcinomas in high incidence. When
FANFT was administered in the diet for 4 or 6
weeks, few tumors were present in the bladder af-
ter two years (18, 19) and none were found in the
bladder at earlier times.
Initiation and Promotion in the
Urinary Bladder
When low doses of several bladder carcinogens
(BBN, FANFT, AAF and 3,3'-dichlorobenzidine)
were administered to rats simultaneously, a syner-
gistic effect was observed with respect to the induc-
tion of bladder cancer (20). If the same chemicals at
the same doses were administered sequentially, the
results were similar (21). However, these experi-
ments involved "complete" carcinogens. A more
specific sequential carcinogenesis model involving
noncarcinogens or cocarcinogens is the model of ini-
tiation and promotion.
Many of the characteristics of initiation and pro-
motion have been demonstrated in the mouse skin
model originally described in the 1940s (22, 23,). In
the past decade, it has become apparent that a simi-
lar mechanism is involved in the carcinogenic pro-
cess in a number of organs including the urinary
bladder epithelium (18, 24, 25). However, prior to
1970, there was some evidence already available
that such a mechanism was involved in urinary
bladder carcinogenesis. These experiments involved
the pellet implantation technique originally de-
scribed by Jull (2). Clayson and Cooper demon-
strated that, although some bladder tumors re-
sulted from the implantation of a pellet into the
bladder, the incidence of bladder tumors was great-
ly increased if the animal was previously treated
with diphenylene oxide. Diphenylene oxide adminis-
tered without subsequent pellet implantation into
the bladder did not induce tumors. Bryan and
Springberg (26) demonstrated that the administra-
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tion of the 8-methyl ether of xanthurenic acid ad-
ministered in a cholesterol pellet significantly in-
creased the incidence of bladder tumors compared
to the cholesterol pellet alone. In addition, they
demonstrated that if the 8-methyl ether of xanthu-
renic acid was administered by subcutaneous injec-
tion to a mouse that also had a cholesterol pellet in
the urinary bladder, a similar incidence of tumors
was induced. However, it was not until the report
by Hicks et al. (24) that a more classical model of ini-
tiation and promotion was demonstrated for the uri-
nary bladder. In their experiments, a subearcino-
genic dose of MNU was injected intravesicularly,
followed by the oral administration of sodium sac-
charin or sodium cyclamate in the diet. If adminis-
tered alone, these compounds did not produce a sig-
nificant incidence of bladder tumors. However, the
sequential administration of MNU followed by so-
dium cyclamate or sodium saccharin resulted in a
markedly increased incidence of bladder tumors.
In our laboratory, we have utilized the FANFT
model in inbred Fischer male rats for the study of
multistage carcinogenesis of the urinary bladder.
FANFT has served as the initiator and is adminis-
tered in the diet at a level of 0.2%. Promoting sub-
stances have included sodium saccharin (5% of the
diet) and tryptophan (2% of the diet). Our initial
study (18) involved the administration of FANFT
for 6 weeks, followed by either sodium saccharin or
DL-tryptophan, beginning either immediately after
the FANFT or after a delay of 6 weeks during
which time the rats were fed control diet. The re-
sults of this experiment are summarized in Table 1.
Both chemicals served as promoting substances in
this model, and the 6 week delay did not appear to
significantly affect the results. During this 6 week
period, the FANFT was completely excreted from
the body (27) and the mild hyperplasia present after
6 weeks of FANFT administration regressed so
that the bladder epithelium appeared histologically
normal (10, 17). These data suggested that the two
stage model of initiation and promotion was appli-
cable to urinary bladder carcinogenesis and that ini-
tiation was irreversible, similar to findings in other
models (23). However, 6 weeks of FANFT followed
by control diet for 2 years produced one papilloma
and four carcinomas of the bladder in 20 rats. Al-
though these tumors were small and each bladder
contained only one tumor (in contrast to the large
and multiple bladder tumors with saccharin and
tryptophan), this was an unacceptably high level of
tumors for the "initiator only group". The experi-
ment was repeated with the use of FANFT for 4
weeks and sodium saccharin or L-tryptophan (in-
stead of the racemic mixture) as promoters (19). Re-
sults of this experiment are also shown in Table 1.
Although the tumor incidence is considerably less
than obtained after 6 weeks of FANFT, the com-
bined treatment with FANFT for 4 weeks followed
by sodium saccharin induced a significant incidence
of bladder tumors. The L-tryptophan treatment,
however, was not statistically significant, although
with a larger group of animals this may achieve
significance.
The promoting activity of sodium saccharin in
this model is similar to that originally described in
the MNU model (24) and subsequently in the BBN
model by Ito and his colleagues (25). The results
with tryptophan, although suggestive of promoting
activity, are not conclusive. However, with mice, L-
tryptophan administered after FANFT initiation
also induced bladder tumors, although, again, the in-
cidence was not statistically significant (28). DL-
Tryptophan administered to dogs after aromatic
amines, 2-naphthylamine and 4-aminobiphenyl, also
was suggestive of promoting activity, although the
number of dogs used was small (29).
Sodium Saccharin
The above experiments are strongly supportive
of the initiation and promotion model in urinary
Table 1. Initiation-promotion for the rat urinary bladder using FANFT as initiator.a
6 Weeks of FANFT 4 Weeks of FANFT
Rats with bladder tumors Rats with bladder tumors
Treatment group No. of rats Papilloma Carcinoma No. of rats Papilloma Carcinoma
FANFT--Saccharin 19 0 18 26 2 5
FANFT-"Control--Saccharin 18 0 13
Control--Saccharin 20 0 0 26 0 0
FANFT-"Tryptophan 19 1 10 26 3 2
FANFT--Control----Tryptophan 20 4 10
Control-"Tryptophan 19 0 0 26 0 0
FANFT-"Control 20 1 4 25 1 0
FANFT (long-term) 40 0 40 8 0 8
Control 42 0 0 27 0 0
aData ofCohen et al. (18) and Fukushima et al. (11,19).
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bladder carcinogenesis. However, the critical expe-
riment wherein sodium saccharin is administered
first followed by FANFT has not yet been com-
pleted. Nevertheless, the model of FANFT followed
by sodium saccharin has many of the properties
usually attributed to initiation and promotion.
FANFT is a strongly mutagenic chemical (30) in va-
rious bacterial and cell culture assays, and the urine
of animals administered FANFT contains strong
mutagenic activity. Sodium saccharin (31, 32) and
tryptophan (33), in contrast, are not mutagenic in
these in vitro assays nor are the metabolites of
tryptophan. Also, FANFT administration appears
to irreversibly initiate the process since sodium sac-
charin and tryptophan could be administered with
at least a 6-week delay after discontinuing FANFT
administration (18). Another property of tumor pro-
moters is the induction of cell proliferation in the
target tissue regardless of whether the tissue has
been initiated or not (23). Initial reports with sodium
saccharin indicated that hyperplasia was an infre-
quent result of even high doses of the chemical (24,
34). However, using the highly sensitive techniques
of scanning electron microscopy and autoradiog-
raphy, we were able to demonstrate that sodium
saccharin does increase the rate of proliferation in
the bladder mucosa, but the increase is slight and
multifocal (35). Multiple serial sections of the uri-
nary bladder mucosa evaluated by light microscopy
were able to eventually demonstrate simple hyper-
plastic areas. The changes induced by sodium sac-
charin detected by scanning electron microscopy
and autoradiography are dose-responsive (36), with
a range similar to that found by Ito and his col-
leagues (25).
The mechanism of sodium saccharin's effect on
the urinary bladder is unknown at this time. It re-
mains unclear as to whether sodium saccharin acts
directly on the bladder mucosa or whether it alters
the urine or other physiological system in such a
way that it indirectly produces its effect. Initially,
sodium saccharin was considered to be acting
through the production of calculi or an increase in
the size and/or the number of crystals in the urine
£32). In our experiment, using 4 weeks of FANFT as
initiator followed by sodium saccharin of L-trypto-
phan as promoter, we periodically examined the
urine of these animals for the presence of calculi,
the number and size of the crystals in the urine
(predominantly "triple phosphate" crystals) and also
the osmolality and various electrolytes (37). During
the entire course of this experiment, calculi were
not found in the urine, and the number and size of
the crystals were not increased. The osmolality of
the urine in animals fed sodium saccharin in the diet
was somewhat less than that in the control animals,
and the urinary volume was greatly increased, sec-
ondary to the increased fluid intake by these ani-
mals. The urinary sodium concentration was slight-
ly increased compared to that in control rat urine,
but the total amount of sodium excreted was con-
siderably more than normal. These results are ex-
pected following the intake of a large amount of the
sodium salt of a weak acid associated with an in-
creased water intake. None of these changes in the
urine were found in the rats fed L-tryptophan. How-
ever, an interesting finding in the urine of rats fed
either sodium saccharin or L-tryptophan was de-
creased glucose concentration in the urine and sub-
sequently also in the serum.
In addition to the changes in the urinary bladder,
we have recently demonstrated that sodium saccha-
rin also has effects on the rat kidney. Male Fischer
rats frequently develop an interstitial nephritis
with age, particularly after the age of 18 months
(19). Rats fed sodium saccharin infrequently showed
these changes in the kidney even after 2 years (19),
regardless of other treatment. This inhibition of the
formation of interstitial nephritis was not observed
in rats fed L-tryptophan.
In contrast to the frequent finding of interstitial
nephritis in older male Fischer rats, the appearance
of urothelial hyperplasia or tumors of the urinary
bladder, ureters, or renal pelvis is unusual in con-
trol Fischer rats. In rats fed sodium saccharin,
whether FANFT was previously administered or
not, approximately half of the rats fed sodium sac-
charin developed marked hyperplasia of the renal
pelvic structures (38). The hyperplasia in the renal
pelvis was considerably more than in the urinary
bladder, and frequently, there was nodular and pap-
illary hyperplasia ofthe renal pelvic epithelium, par-
ticularly at the junction between the papilla and pel-
vis. FANFT initiation did not appear to alter the in-
cidence of this hyperplastic change, and only one rat
administered sodium saccharin (pretreated with cy-
clophosphamide and FANFT) developed a transi-
tional cell carcinoma ofthe renal pelvis.
Role of Urine
Urinary bladder carcinogenesis has long been
considered to result from exposure of the urinary
bladder epithelium to carcinogens in the urine, the
so-called urogenous or carrier theory. The ability of
the urine to concentrate solutes compared to the
level in serum is one of the reasons for this mecha-
nism. Scott and Boyd (39) demonstrated that dogs
fed 2-naphthylamine and having the urine diverted
to the sigmoid colon by ureterosigmoidostomies pre-
vented the induction of bladder tumors. McDonald
and Lund (40) tied off the top half of the bladder,
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preventing exposure to the urine flow but leaving
the bottom half exposed to urine. The dogs were
fed 2-naphthylamine, and tumors were found only in
the half of the bladder exposed to urine. An indica-
tion that urine might be more than simply a carrier
of carcinogens was suggested by the experiments of
Chapman et al. (41), in which paraffin wax pellets
were inserted into both halves of a bladder which
had been divided in half by tying a suture around
the mid-portion of the bladder. Again, tumors, al-
though benign, were induced only in the portion of
the bladder exposed to urine. The presence of cal-
culi greatly increased the incidence of bladder tu-
mors in the portion of the bladder exposed to urine.
However, the addition of 3-hydroxyanthranilic acid
to the paraffin wax pellet did not enhance the tu-
mor incidence, possibly because of the very slow re-
lease ofthis chemical from the pellets.
Rowland et al. (42) recently provided additional
evidence that urine is more than merely a carrier of
carcinogens. FANFT was fed at a dose of 0.2% of
the diet for 14 weeks. At that time, half of the rats
underwent urinary diversion with bilateral uretero-
sigmoidostomies and the other half were sham oper-
ated. Eight of the 19 the sham-operated animals de-
veloped bladder tumors within 6 months of the time
of operation compared to only one of 18 rats that
had undergone urinary diversion. These data would
indicate that urine is acting as a promoting sub-
stance since it was required for the appearance of
tumors despite the administration of an apparently
carcinogenic dose of FANFT. Oyasu et al. (43) also
demonstrated promoting activity for urine using
their heterotopic bladder model. In this model, uri-
nary bladders are transplanted subcutaneously into
syngeneic rats attached to an Ommaya reservoir
through which substances can be injected. If BBN
was given to rats and the bladder then transplanted
as a heterotopic bladder instilled with 0.9% sodium
chloride (saline), no tumors developed in the hetero-
topic bladder after 38 weeks and two of 13 rats had
tumors in the heterotopic bladder after 44 weeks. In
comparison, if the BBN was followed by instillation
of urine adjusted as to be equiosmolal with the sa-
line solution, eight of 19 animals had bladder tumors
in the heterotopic bladder after 38 weeks and eight
of 14 had tumors after 44 weeks. If either saline or
urine was instilled without previous BBN adminis-
tration, no tumors appeared in the heterotopic or
host bladder. Oyasu and his colleagues also demon-
strated (44) that urine increased ornithine-decarbox-
ylase activity in an in vitro assay of rat bladder tu-
mors, but it was not as potent as the phorbol ester,
12-0-tetradecanoylphorbol-13-acetate (TPA). Al-
though increased activity was also induced by the
presence of 3-hydroxyanthranilic acid, a metabolite
of tryptophan, most of the activity in urine was
present in the fraction with a molecular weight
greater than 10,000 daltons.
Although those data would indicate that urine, or
some substance(s) in urine has promoting activity, it
must be considerably less potent than exogenous
promoting substances such as sodium saccharin. For
example, FANFT administered as 0.2% of the diet
for 6 weeks followed by control diet resulted in the
induction of bladder tumors in five of 20 rats,
whereas 18 of 19 rats administered 5% sodium sac-
charin after the FANFT developed bladder tumors
(18).
In the model of initiation and promotion proposed
by Boutwell (22), he divided promotion into at least
two phases. The first phase of promotion was called
conversion and appeared to require something more
than mere proliferation of the target tissue after ini-
tiation. Thus, croton oil could act as a converting
agent, but turpentine, an inducer of cell prolifera-
tion on the mouse skin, had considerably weaker ac-
tivity. The second phase of promotion was referred
to as propagation, and this appeared to require only
the administration of a substance that increased cell
proliferation. Thus, either croton oil or turpentine
were active in this phase. Slaga and his colleagues
(45) have recently refined this experiment consider-
ably using the purified ingredient of croton oil,
TPA, as a converting agent and mezerein as the
propagating agent. The experiments of Slaga would
also indicate that the period required for conversion
is relatively short. The propagation phase appears
to be the rate limiting phase of tumor induction.
Using this model of promotion, it is possible that
urine is acting as a propagating agent rather than
as a complete promoter. Thus, in this model, very
brief exposure to an initiating agent and exposure
to a converting agent for a somewhat longer period
of time would be enough to induce bladder cancer,
since urine would always be present as an endog-
enous propagating agent. Without additional expo-
sure to stronger exogenous promoting substances, a
low incidence of bladder tumors would be expected
despite only brief exposure to carcinogens. A simi-
lar model can be formulated for most epithelial tis-
sues with some normally present endogenous agent
acting as the propagating substance. This would
help to explain induction of tumors in certain in-
stances involving very short exposures to carcino-
gens and also would partially explain the relatively
long periods of time necessary for the induction of
most tumors.
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Cell Proliferation and Bladder
Carcinogenesis
The above experiments provide evidence that the
model of initiation-promotion is relevant to urinary
bladder carcinogenesis. In the MNU model, the initi-
ating dose of the MNU is applied as a single instilla-
tion of chemical into the urinary bladder (24) similar
to the model of initiation in the mouse skin tumor
system. With FANFT, however, administration of
an initiating dose requires 4 to 6 weeks of the chem-
ical in the diet at a level of 0.2% (18). One of the
characteristics for initiating agents in studies in
other systems is the necessity of at least one cell cy-
cle being completed to fix initiation irreversibly (23).
The urinary bladder normally has a very low rate of
cell turnover; the labeling index is approximately 4
per 10,000 epithelial cells (35). We postulated that
administration of FANFT to an animal with a prolif-
erating bladder mucosa might reduce the required
time of administration (38). The results are shown in
Table 2. The marked regenerative hyperplasia of
the bladder was induced by the Shirai method (46)
of freeze ulceration or by cyclophosphamide injec-
tion (1, 2). In Group 1, ulceration was followed imme-
diately by the oral administration of 0.2% FANFT
for 2 weeks and then was promoted by sodium sac-
charin administered at 5% of the diet for the re-
maining 102 weeks of the experiment. A similar
protocol using cyclophosphamide as the ulcer induc-
ing agent is Group 11. The other groups served as
the appropriate control groups. Two weeks of
FANFT followed by sodium saccharin was insuffi-
cient for the induction of bladder tumors except for
one small papilloma (group 5). FANFT (group 6) and
saccharin (groups 7 and 17) alone and the ulcer
(group 4) alone were insufficient for inducing tu-
mors. The rats administered FANFT after ulcera-
tion and then given sodium saccharin (group 1) had
bladder tumors as predicted. Similar results oc-
curred with cyclophosphamide (group 11). However,
the administration of sodiuim saccharin, either im-
mediately after the ulcer (group 10) or after two
weeks of control diet (group 3) resulted in compara-
ble incidences of bladder tumors. A similar result
was obtained with cyclophosphamide as the ulcerat-
ing agent (groups 15 and 13, respectively). As men-
tioned above, FANFT and cyclophosphamide pro-
duce urine in the rat containing mutagenic activity
in in vitro assays. In this experiment, however, the
presence of FANFT did not increase the incidence
of bladder tumors compared to the control if the ul-
cer was induced before saccharin, and cyclophospha-
mide did not give significantly greater results than
ulceration by freezing, a method which is nonmuta-
genic. These data suggest that sodium saccharin is
carcinogenic when administered to an animal with a
proliferating urinary bladder epithelium. They also
suggest that mutation, strictly defined as a change
in nucleotide content (primarily defined as the re-
sult of the Ames assay), is not necessary for the car-
cinogenic process. Although a point mutation may
not be involved in the carcinogenic process, other
genetic changes such as recombination or transloca-
tion are possible. In vitro assays involving Saccharo-
myces have indicated that sodium saccharin is able
to cause these genetic changes (47). Additional stud-
ies will be required to evaluate this possibility.
Results of the above experiment with sodium sac-
charin and ulceration are quite consistent with the
Table 2. Effect of ulceration on urinary bladder carcinogenesis.
No. of rats with
Group no. Treatment groupa No. of rats bladder tumors (%)
1 Ulcer- FANFT- Saccharin 22 3 (14)
2 Ulcer-FANFT -Control 22 0
3 Ulcer- Control- Saccharin 19 4 (21)
4 Ulcer -Control 23 0
5 FANFT --Saccharin 21 1 (5)
6 FANFT --Control 19 0
7 Control Saccharin 17 0
8 FANFT -Ulcer --Saccharin 22 8 (36)
9 FANFT-'Ulcer--Control 21 2 (10)
10 Ulcer -Saccharin 21 4 (19)
11 CP-FANFT- --Saccharin 22 7 (32)
12 CP -FANFT---Control 9 0
13 CP-'Control -Saccharin 16 5 (31)
14 CP-Control 7 1 (14)
15 CP --Saccharin 17 6 (35)
16 Control 32 0
17 Saccharin 24 0
aFANFT = 0.2% N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide; saccharin = 5% sodium saccharin; ulcer = freeze ulceration; CP
= cyclophosphamide-induced ulceration (100 mg/kg IP); Control = control diet without added test chemical.
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results of other experiments with sodium saccharin.
Sodium saccharin administration to a single genera-
tion of rats induced a few bladder tumors, but the
incidence has generally been 1% or less (24, 32, 34).
However, if administered to pregnant rats and to
the offspring during the suckling period and after
weaning, a greater incidence of bladder tumors was
induced (34). In utero, the urinary bladder is in a
state of active proliferation, whereas almost imme-
diately after the birth the bladder attains its adult
slow turnover rate (2). Thus, the in utero exposure
is similar to the exposure after ulceration with the
increased proliferation rate.
Sodium saccharin was initially shown to be car-
cinogenic for the urinary bladder in experiments in
which the chemical was administered in a choles-
terol pellet inserted into the urinary bladder (48).
We have demonstrated that the surgical procedure
involved in the insertion of the pellet induced the
same type of proliferation as that following freeze
ulceration with approximately the same kinetics of
regeneration and repair (11). However, in the pellet
experiment, sodium saccharin was leeched from the
pellet within a few days of insertion of the pellet.
One could envision a process of multistage carcino-
genesis in which the saccharin is exposed to a uri-
nary bladder with an increased proliferative rate
following the insertion of the pellet. The propaga-
tion process would continue if the bladder mucosa
was maintained in a state of increased proliferation,
such as provided by the presence of the pellet along
with the urine itself. In such a model, the early
events of carcinogenesis, initiation and conversion
(22) would be due to the combination of the surgical
technique inducing the market increase in cell pro-
liferation and exposure to sodium saccharin. The
pellet and urine would then be acting as the propa-
gating agents.
Another possible example presenting a mecha-
nism similar to that illustrated in this experiment is
schistosomiasis. Urological schistosomiasis is asso-
ciated with a greatly increased risk of developing
bladder cancer (1, 2), particularly squamous cell car-
cinoma. Recent evidence suggests that nitrosamines
are generated during the active inflammation that
occurs with schistosomal infections, possibly by in
situ generation by the reaction of nitrite with sec-
ondary amines in an acid medium. Chronic schisto-
somiasis is well known to cause increased prolifer-
ative processes in the urinary bladder epithelium in
humans as well as in the nonhuman primate model.
If applicable to the human situation, these experi-
ments suggest possible populations at increased
risk ofdevelopment of bladder carcinoma if exposed
to various environmental agents, whether complete
carcinogens or substances such as the type repre-
sented by sodium saccharin. It is known that males
have an increased risk of developing bladder cancer
compared to females (2). Could this be related to the
development of prostatism in elderly males with
consequent proliferation changes in the bladder epi-
thelium? Is exposure to certain chemicals in utero
and shortly after birth responsible for an increased
risk of development of bladder cancer since the epi-
thelium is proliferating during these times? Are
people who have recurrent episodes of acute cysti-
tis with its accompanying regenerative hyperplasia
at increased risk if exposed to certain chemicals
such as sodium saccharin or cigarette smoking? We
obviously have a great deal to learn about bladder
carcinogenesis in humans, but hopefully the results
in these animal models will provide clues for us to
evaluate the human situation.
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